Target on Ebola

Public Health Agency of Canada researchers have shown that a cocktail of three antibodies, dubbed ZMab, improved the survival of nonhuman primates infected by Ebola virus.¹ ZMab is licensed to Defyrus Inc., which plans to establish commercial-scale manufacture of the therapy and carry out biodistribution and toxicology studies.

An ongoing challenge for Ebola therapies is the ability to treat the disease several days after infection, when patients typically present at the clinic. Ebola runs its course within 14-21 days, with patients first presenting nonspecific flu-like symptoms. Patients then progress and show impaired kidney and liver function, and in some cases internal and external bleeding...